Esophageal Carcinoma Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma
This multicentered clinical trial is going to find out the radio-sensitization action of sodium glycididazole in radiochemotherapy for esophageal cancer.
Esophageal cancer is one of the most frequent causes of cancer death in the world. The most
common type of esophageal cancer is squamous cell carcinoma (SCC) in China. Although
concurrent radiochemotherapy is recommended as the standard treatment for advanced
esophageal carcinoma, the local failure still reaches up to 44%-54%.
Sodium Glycididazole(CMNa) is a radiosensitive drug for hypoxic tumor cells. Clinical trials
showed that CMNa can improve local control rate and survival rate of esophageal cancer. This
study is going to confirm the efficacy and safety of CMNa in concurrent radiochemotherapy of
radiotherapy and 5-FU+DDP for esophageal squamous carcinoma.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02355249 -
Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer
|
Phase 3 | |
| Completed |
NCT01691625 -
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
|
N/A | |
| Not yet recruiting |
NCT05937438 -
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05777707 -
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02527057 -
Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
|
N/A | |
| Withdrawn |
NCT00636298 -
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
|
Phase 2 | |
| Recruiting |
NCT06009705 -
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
|
||
| Recruiting |
NCT04652180 -
Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .
|
N/A | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06199895 -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
|
Phase 2 | |
| Completed |
NCT00590031 -
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
|
Phase 2 | |
| Active, not recruiting |
NCT00176800 -
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
|
Phase 2 | |
| Completed |
NCT03099382 -
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04607590 -
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
|
||
| Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
| Completed |
NCT01855854 -
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
|
Phase 2 | |
| Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 |